600196 Shanghai Fosun Pharmaceutical(Group)Co., Ltd.
Noon Closed 05-06 11:29:57
24.17
+0.50
+2.11%
High
24.20
Low
23.82
Vol
9.27M
Open
23.82
D1 Closing
23.67
Amplitude
1.61%
Mkt Cap
64.58B
Tradable Cap
51.19B
Total Shares
2.67B
T/O
223.00M
T/O Rate
0.44%
Tradable Shares
2.12B
P/B
1.36
ROE
--
EPS
0.00
52wk High
--
52wk Low
--
P/E
--
Dividend
--
Div.Yield
--
ROA
--
Time
5D
D
W
M
News
New Post(s)
Profile
Shanghai Fosun Pharma Says Unit Recently Received Approval From Nmpa Of China
Reuters · 01-15
Shanghai Fosun Pharma Says Unit Recently Received Approval From Nmpa Of China
Shanghai Fosun Pharma Says New Drug Application Of Famotidine Injection Accepted By China NMPA
Reuters · 01-10
Shanghai Fosun Pharma Says New Drug Application Of Famotidine Injection Accepted By China NMPA
Load more
Introduction
Company Name.
上海复星医药(集团)股份有限公司
Industry:
医药制造业
Listing Date:
1998-08-07
Main Business:
上海复星医药(集团)股份有限公司主营业务是制药、医疗器械、医学诊断、医疗健康服务。主要产品为心血管系统疾病治疗领域核心产品、中枢神经系统疾病治疗领域核心产品、血液系统疾病治疗领域核心产品、代谢及消化系统疾病治疗领域核心产品、抗感染疾病治疗领域核心产品、抗肿瘤治疗领域核心产品、原料药和中间体核心产品。根据中华人民共和国工信部中国医药工业信息中心颁布的2018年度中国医药工业百强企业榜单,本集团位列第7;根据IQVIA统计,2019年本集团生产的医院用处方药的销售收入位列全国第10。作为全球最大的抗疟药生产研发制造企业之一,本集团已成为全球基金、联合国儿童基金会、世界卫生组织及非洲各国药品采购中心的抗疟药供应商。本集团持续保持健康高质量发展。由米内研究院主办的“中国医药工业百强系列榜单”,本集团成功入选“2022年度中国化药企业TOP100排行榜”,位列中国化药企业百强榜第6位;根据IQVIA统计,2023年第一季度本集团的医院用处方药销售收入位列全国第12位;根据全球医药智库信息平台InformaPharmaIntelligence发布的《2023年医药研发趋势年度分析》白皮书,本集团再次入选“全球医药企业研发管线规模Top25”。
Issue price:
7.15
{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"Shanghai Fosun Pharmaceutical(Group)Co., Ltd.","latestPrice":24.17,"timestamp":1714966197000,"preClose":23.67,"halted":0,"volume":9274179,"delay":0,"changeRate":0.0211,"floatShares":2118000000,"shares":2672000000,"eps":0.7518,"marketStatus":"Noon Closed","change":0.5,"latestTime":"05-06 11:29:57","open":23.82,"high":24.2,"low":23.82,"amount":223000000,"amplitude":0.0161,"askPrice":24.17,"askSize":3,"bidPrice":24.16,"bidSize":749,"shortable":0,"etf":0,"ttmEps":0.7518,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1714971600000},"marketStatusCode":3,"adr":0,"adjPreClose":23.67,"symbolType":"stock","openAndCloseTimeList":[[1714959000000,1714966200000],[1714971600000,1714978800000]],"highLimit":26.04,"lowLimit":21.3,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2672398711,"isCdr":false,"pbRate":1.36,"roa":"--","peRate":32.149508,"roe":"1.33%","epsLYR":0.89,"committee":-0.559937,"marketValue":64592000000,"turnoverRate":0.0044,"status":0,"hkstockBrief":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"FOSUN PHARMA","latestPrice":12.84,"timestamp":1714969808169,"preClose":12.58,"halted":0,"volume":2927118,"delay":0,"premium":"-50.94"},"floatMarketCap":51204000000},"requestUrl":"/m/hq/s/600196","defaultTab":"news","newsList":[{"id":"2403016843","title":"Shanghai Fosun Pharma Says Unit Recently Received Approval From Nmpa Of China","url":"https://stock-news.laohu8.com/highlight/detail?id=2403016843","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2403016843?lang=en_us&edition=fundamental","pubTime":"2024-01-15 20:35","pubTimestamp":1705322103,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>:Unit Recently Received Approval From Nmpa Of People'S Republic Of China For Clinical Trial Of Xh-S004 Tablets.Further Company Coverage: 600196.Ss. ((Reuters.Briefs@Thomsonreuters.Com;)).","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.trkd.thomsonreuters.com","is_publish_highlight":false,"gpt_icon":0},{"id":"2402170311","title":"Shanghai Fosun Pharma Says New Drug Application Of Famotidine Injection Accepted By China NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2402170311","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2402170311?lang=en_us&edition=fundamental","pubTime":"2024-01-10 18:25","pubTimestamp":1704882352,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>:New Drug Application Of Famotidine Injection Independently Developed By Unit Accepted By China Nmpa.Further Company Coverage: 600196.Ss.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.trkd.thomsonreuters.com","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","stockEarnings":[{"period":"1week","weight":0.0404},{"period":"1month","weight":0.026},{"period":"3month","weight":0.0848},{"period":"6month","weight":-0.1642},{"period":"1year","weight":-0.2427},{"period":"ytd","weight":-0.0543}],"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","perCapita":"--","boardName":"医药制造业","registeredCapital":"267239万元","compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":0.0209},{"period":"3month","weight":0.1134},{"period":"6month","weight":0.0317},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":0.0437}],"survey":" 上海复星医药(集团)股份有限公司主营业务是制药、医疗器械、医学诊断、医疗健康服务。主要产品为心血管系统疾病治疗领域核心产品、中枢神经系统疾病治疗领域核心产品、血液系统疾病治疗领域核心产品、代谢及消化系统疾病治疗领域核心产品、抗感染疾病治疗领域核心产品、抗肿瘤治疗领域核心产品、原料药和中间体核心产品。根据中华人民共和国工信部中国医药工业信息中心颁布的2018年度中国医药工业百强企业榜单,本集团位列第7;根据IQVIA统计,2019年本集团生产的医院用处方药的销售收入位列全国第10。作为全球最大的抗疟药生产研发制造企业之一,本集团已成为全球基金、联合国儿童基金会、世界卫生组织及非洲各国药品采购中心的抗疟药供应商。本集团持续保持健康高质量发展。由米内研究院主办的“中国医药工业百强系列榜单”,本集团成功入选“2022年度中国化药企业TOP100排行榜”,位列中国化药企业百强榜第6位;根据IQVIA统计,2023年第一季度本集团的医院用处方药销售收入位列全国第12位;根据全球医药智库信息平台InformaPharmaIntelligence发布的《2023年医药研发趋势年度分析》白皮书,本集团再次入选“全球医药企业研发管线规模Top25”。","serverTime":1714970234106,"listedPrice":7.15,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shanghai Fosun Pharmaceutical(Group)Co., Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shanghai Fosun Pharmaceutical(Group)Co., Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shanghai Fosun Pharmaceutical(Group)Co., Ltd.,600196,Shanghai Fosun Pharmaceutical(Group)Co., Ltd.股票,Shanghai Fosun Pharmaceutical(Group)Co., Ltd.股票老虎,Shanghai Fosun Pharmaceutical(Group)Co., Ltd.股票老虎国际,Shanghai Fosun Pharmaceutical(Group)Co., Ltd.行情,Shanghai Fosun Pharmaceutical(Group)Co., Ltd.股票行情,Shanghai Fosun Pharmaceutical(Group)Co., Ltd.股价,Shanghai Fosun Pharmaceutical(Group)Co., Ltd.股市,Shanghai Fosun Pharmaceutical(Group)Co., Ltd.股票价格,Shanghai Fosun Pharmaceutical(Group)Co., Ltd.股票交易,Shanghai Fosun Pharmaceutical(Group)Co., Ltd.股票购买,Shanghai Fosun Pharmaceutical(Group)Co., Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shanghai Fosun Pharmaceutical(Group)Co., Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shanghai Fosun Pharmaceutical(Group)Co., Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}